Comparison of the cervista HPV HR test and luminex XMAP technology for the diagnosis of cervical intraepithelial neoplasia

Zhao, Peiyu; Jiang, Huici; Li, Yue; Wang, Jinbo; Zhang, Tingting; Liu, Cheng-hua; Song, Liwen; Cheng, Jiajing

doi:10.1016/j.ejogrb.2017.05.012

Cited by 5 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Cervista HPV HR assay, using 3 different oligonucleotide mixtures, subdivides 14 types of hrHPV into A5/6, A7, and A9 groups. An A5/A6 oligonucleotide probe mixture is used to detect HPV‐51, ‐56, and ‐66 (the A5/A6 group of HPV); an A7 oligonucleotide probe mixture is used for HPV‐18, ‐39, ‐45, ‐59, and ‐68 (the A7 group of HPV); and an A9 oligonucleotide probe mixture is used for HPV‐16, ‐31, ‐33, ‐35, ‐52, and ‐58 (the A9 group of HPV) . The cobas HPV test was performed to detect 14 hrHPV genotypes (HPV‐16, ‐18, ‐31, ‐33, ‐35, ‐39, ‐45, ‐51, ‐52, ‐56, ‐58, ‐59, ‐66, and ‐68) according to the manufacturer’s protocol, which specifically identifies HPV‐16/18 and concurrently detects the rest of the high‐risk genotypes as a mixed result.…”

Section: Methodsmentioning

confidence: 99%

“…An A5/A6 oligonucleotide probe mixture is used to detect HPV-51, -56, and -66 (the A5/A6 group Cancer Cytopathology April 2019 of HPV); an A7 oligonucleotide probe mixture is used for HPV-18, -39, -45, -59, and -68 (the A7 group of HPV); and an A9 oligonucleotide probe mixture is used for HPV-16, -31, -33, -35 -52, and -58 (the A9 group of HPV). [10][11][12][13] The cobas HPV test was performed to detect 14 hrHPV genotypes (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68) according to the manufacturer's protocol, which specifically identifies HPV-16/18 and concurrently detects the rest of the high-risk genotypes as a mixed result. hrHPV DNAs were amplified and detected on the cobas 4800 analyzer and the 330-base pair β-globin was amplified and detected as an internal control of the testing processes.…”

Section: Pap Testmentioning

confidence: 99%

See 1 more Smart Citation

Follow‐up with histopathology and HPV testing on LSIL cytology in China’s largest academic woman’s hospital

Tao

Zhang

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

Background Cervical cancer remains a major health problem in China. To provide baseline data for establishing the appropriate screening strategy, the authors investigated the histopathologic follow‐up and human papillomavirus (HPV) testing results of low‐grade squamous intraepithelial lesion (LSIL) cytology in the Chinese Largest Women Hospital. Methods Women with LSIL cytology, human papillomavirus (HPV) testing, and immediate histopathologic follow‐up between 2011 and 2016 were analyzed. Results The frequency of LSIL among 1,095,022 Papanicolaou (Pap) tests was 1.4%, and was significantly higher in cases using liquid‐based cytology (LBC; 1.5%‐1.6%) compared with conventional Pap smears (CPS; 0.5%). The CPS method had performance for predicting cervical intraepithelial neoplasia (CIN) that was comparable to that of LBC (75% vs 69.1% and 71.9%). Among 8079 LSIL cases with an immediate histopathologic diagnosis, CIN‐2/3 or higher (CIN‐2/3+) was found in 11.9% of cases and carcinoma in 0.3% of cases. A total of 158 patients (15.7%) with HPV‐positive LSIL had a diagnosis of CIN‐2/3 compared with 18 patients (5.5%) with HPV‐negative LSIL. In postmenopausal women with LSIL cytology, the detection rate for CIN‐2/3 in HPV‐negative patients was significant lower than that in HPV‐positive patients. Furthermore, HPV type 16 (HPV‐16) was the most common genotype noted in patients with CIN‐2+ lesions, whereas HPV‐18 was the most common in patients with CIN‐1. Conclusions Although its reporting rate is lower than that of LBC, CPS is useful due to its low cost and comparable predictive value. HPV testing is helpful for stratifying postmenopausal women with LSIL into lower and higher risk groups. HPV‐16 is the most commonly identified genotype in CIN‐2+ lesions diagnosed in Chinese women with LSIL cytology, whereas HPV‐18 is the most commonly identified genotype in patients with CIN‐1 lesions.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Pap Testmentioning

confidence: 99%

Follow‐up with histopathology and HPV testing on LSIL cytology in China’s largest academic woman’s hospital

Tao

Zhang

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

show abstract

“…Therefore, the clinical application of sequencing-dependent SNV detection methods is limited. Conversely, the detection equipment of microsphere used in this study has been routinely employed in many clinical units, as well as widely used in cytokine detection ( Montoya et al, 2017 ), HPV typing ( Pesic et al, 2020 ; Zhao et al, 2017 ), and SARS-CoV-2 serosurveillance ( Marien et al, 2021 ). Therefore, it is easier to promote the MMPA system in clinical applications.…”

Section: Discussionmentioning

confidence: 99%

An encodable multiplex microsphere-phase amplification sensing platform detects SARS-CoV-2 mutations

Zhong

Wang

et al. 2022

Biosensors and Bioelectronics

View full text Add to dashboard Cite

SARS-CoV-2 variants of concern (VOCs) contain several single-nucleotide variants (SNVs) at key sites in the receptor-binding region (RBD) that enhance infectivity and transmission, as well as cause immune escape, resulting in an aggravation of the coronavirus disease 2019 (COVID-19) pandemic. Emerging VOCs have sparked the need for a diagnostic method capable of simultaneously monitoring these SNVs. To date, no highly sensitive, efficient clinical tool exists to monitor SNVs simultaneously. Here, an encodable multiplex microsphere-phase amplification (MMPA) sensing platform that combines primer-coded microsphere technology with dual fluorescence decoding strategy to detect SARS-CoV-2 RNA and simultaneously identify 10 key SNVs in the RBD. MMPA limits the amplification refractory mutation system PCR (ARMS-PCR) reaction for specific target sequence to the surface of a microsphere with specific fluorescence coding. This effectively solves the problem of non-specific amplification among primers and probes in multiplex PCR. For signal detection, specific fluorescence codes inside microspheres are used to determine the corresponding relationship between the microspheres and the SNV sites, while the report probes hybridized with PCR products are used to detect the microsphere amplification intensity. The MMPA platform offers a lower SARS-CoV-2 RNA detection limit of 28 copies/reaction, the ability to detect a respiratory pathogen panel without cross-reactivity, and a SNV analysis accuracy level comparable to that of sequencing. Moreover, this super-multiple parallel SNVs detection method enables a timely updating of the panel of detected SNVs that accompanies changing VOCs, and presents a clinical availability that traditional sequencing methods do not.

show abstract

“…To read the assay, the fluorescence signals are measured from each bead—one from the capture microbead to identify the biomarker it targets, and another for the detection antibody to quantify the amount of the biomarker bound to the bead. xMAP has been used for nucleic acid assays and immunoassays to diagnose diseases like human papillomavirus, 107 , 108 colorectal cancer, [ 109 ] Alzheimer’s disease, [ 110 ] and Salmonella , Cryptosporidium infection. [ 111 ] The xMAP system has also been used to quantify the host antibody response to infection by Sendai virus, rabbit hemorrhagic disease virus, rabbit rotavirus, [ 112 ] Newcastle disease virus, avian influenza virus, [ 113 ] bronchitis virus, [ 114 ] and adenovirus.…”

Section: Bead-based Assaysmentioning

confidence: 99%

Engineering innovative interfaces for point-of-care diagnostics

Burrow

Heggestad

Kinnamon

et al. 2023

Current Opinion in Colloid & Interface Science

View full text Add to dashboard Cite

Comparison of the cervista HPV HR test and luminex XMAP technology for the diagnosis of cervical intraepithelial neoplasia

Cited by 5 publications

References 38 publications

Follow‐up with histopathology and HPV testing on LSIL cytology in China’s largest academic woman’s hospital

Follow‐up with histopathology and HPV testing on LSIL cytology in China’s largest academic woman’s hospital

An encodable multiplex microsphere-phase amplification sensing platform detects SARS-CoV-2 mutations

Engineering innovative interfaces for point-of-care diagnostics

Contact Info

Product

Resources

About